← Back to Clinical Trials
Recruiting NCT05179616

NCT05179616 Pforzheim Tricuspid Valve Registry - Outcomes of Percutaneous Tricuspid Valve Repair

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05179616
Status Recruiting
Phase
Sponsor Helios Klinikum Pforzheim
Condition Tricuspid Regurgitation
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2020-11-30
Primary Completion 2025-11-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Transcatheter edge-to-edge tricuspid valve repair

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2020-11-30 with a primary completion date of 2025-11-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The Pforzheim Tricuspid Valve Registry study is designed to confirm the safety and performance of the TriClip™ device in a contemporary real-world setting in critically ill patients. The observational trial is a prospective, single arm, open-label, single-center, post market registry.

Eligibility Criteria

Inclusion Criteria: * Subjects (\>=18 years age) have severe tricuspid regurgitation and are symptomatic despite medical therapy. * Subjects eligible to receive the TriClip™ * Subjects must provide written informed consent prior to study procedure. Exclusion Criteria: * Subjects participating in another clinical study that may impact the follow-up or results of this study.

Contact & Investigator

Central Contact

Ilka Ott, MD, PhD

✉ Ilka.Ott@helios-pforzheim.de

📞 +4972319692955

Principal Investigator

Ilka Ott, MD, PhD

PRINCIPAL INVESTIGATOR

Helios Klinikum Pforzheim

Frequently Asked Questions

Who can join the NCT05179616 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Tricuspid Regurgitation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05179616 currently recruiting?

Yes, NCT05179616 is actively recruiting participants. Contact the research team at Ilka.Ott@helios-pforzheim.de for enrollment information.

Where is the NCT05179616 trial being conducted?

This trial is being conducted at Pforzheim, Germany.

Who is sponsoring the NCT05179616 clinical trial?

NCT05179616 is sponsored by Helios Klinikum Pforzheim. The principal investigator is Ilka Ott, MD, PhD at Helios Klinikum Pforzheim. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology